<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27623347</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Single dose of an adenovirus vectored mouse interferon-&#x3b1; protects mice from lethal EV71 challenge.</ArticleTitle><Pagination><StartPage>207</StartPage><EndPage>215</EndPage><MedlinePgn>207-215</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2016.09.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(16)30364-3</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) causes hand-foot-and-mouth diseases as well as neurological complications in young children. Interferon (IFN) can inhibit the replication of many viruses with low cytotoxic effects. Previously, an adenovirus vectored mouse interferon-&#x3b1; (DEF201), subtype 5, was generated by Wu et&#xa0;al, 2007. In this study, the antiviral effects of DEF201 against EV71 were evaluated in a murine model. 6-day-old BALB/c mice were administered a single dose of DEF201 before or after infection with lethal dose of EV71. The survival rate, clinical symptoms, tissue viral loads and histology pathogenesis were evaluated. IFN gene expression following a single dose of DEF201 maintained high concentrations of 100-9000&#xa0;pg/mL for more than 7 days in mice serum. Pre-infection administration of a single dose of 10<sup>6</sup>&#xa0;PFU of DEF201 offered full protection of the mice against EV71 infection compared with the empty Ad5 vector control. In addition, virus load in DEF201-treated mice muscle tissue was significantly decreased as compared with empty vector control. Histopathology analysis revealed that DEF201 significantly prevented the development of severe tissue damage with reduction of viral antigen in the murine muscle tissue. Post-infection treatment at 6&#xa0;h offered full protection and partial protection at 12&#xa0;h, indicating that DEF201 could be used as an anti-EV71 therapeutic agent in early stage of EV71 infection. In addition, our study showed that DEF201 enhanced the neutralization ability of serum in EV71-vaccinated mice, implying that DEF201 could promote the production of specific anti-EV71 antibodies. In conclusion, single dose of DEF201 is highly efficacious as a prophylactic agent against EV71 infection in&#xa0;vivo.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jialei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, MD4 Level 5, 5 Science Drive 2, Singapore 117597, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ennis</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Defyrus Inc., 2 Bloor Street West, Suite 2602, Toronto, ON, M4W 3E2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Defyrus Inc., 2 Bloor Street West, Suite 2602, Toronto, ON, M4W 3E2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Justin Jang Hann</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, MD4 Level 5, 5 Science Drive 2, Singapore 117597, Singapore. Electronic address: miccjh@nus.edu.sg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C554329">Ifna1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="Y">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DEF201</Keyword><Keyword MajorTopicYN="N">EV71</Keyword><Keyword MajorTopicYN="N">Murine model</Keyword><Keyword MajorTopicYN="N">Prophylactic effects</Keyword><Keyword MajorTopicYN="N">Therapeutic effects</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27623347</ArticleId><ArticleId IdType="pmc">PMC7113890</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2016.09.003</ArticleId><ArticleId IdType="pii">S0166-3542(16)30364-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Balachandran S. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J.&#xa0;Virol. 2000;74:1513&#x2013;1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111487</ArticleId><ArticleId IdType="pubmed">10627563</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.L. Inhibition of dengue virus by an ester prodrug of an adenosine analog. Antimicrob. Agents Chemother. 2010;54:3255&#x2013;3261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916325</ArticleId><ArticleId IdType="pubmed">20516277</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A.H. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PloS One. 2013;8:e79783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagley A. Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201) Antivir. Res. 2014;108:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4101997</ArticleId><ArticleId IdType="pubmed">24833276</ArticleId></ArticleIdList></Reference><Reference><Citation>Damjanovic D. Type 1 interferon gene transfer enhances host defense against pulmonary Streptococcus pneumoniae infection via activating innate leukocytes. Mol. Ther. &#x2014; Methods &amp; Clin. Dev. 2014;1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4378291</ArticleId><ArticleId IdType="pubmed">26015944</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelman F.D. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J.&#xa0;Exp. Med. 1991;174:1179&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118981</ArticleId><ArticleId IdType="pubmed">1940796</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowen B.B. Use of recombinant adenovirus vectored consensus IFN-a to avert severe arenavirus infection. PloS One. 2011;6:e26072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200317</ArticleId><ArticleId IdType="pubmed">22039436</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham F.L., Prevec L. Manipulation of adenovirus vectors. In: Murray E.J., editor. vol. 7. Humana Press; Clinton, NJ: 1991. pp. 109&#x2013;128. (Methods in Molecular Biology).</Citation><ArticleIdList><ArticleId IdType="pubmed">21416352</ArticleId></ArticleIdList></Reference><Reference><Citation>Jego G. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19:225&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">12932356</ArticleId></ArticleIdList></Reference><Reference><Citation>Julander J.G., Ennis J., Turner J., Morrey J.D. Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrob. Agents Chemother. 2011;55:2067&#x2013;2073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088275</ArticleId><ArticleId IdType="pubmed">21300837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumaki Y. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse mode. Antivir. Res. 2011;89:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018546</ArticleId><ArticleId IdType="pubmed">21093489</ArticleId></ArticleIdList></Reference><Reference><Citation>Le B.A. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in&#xa0;vivo. Immunity. 2001;14:461&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">11336691</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Yin H., An Z., Feng Z. Considerations for developing an immunization strategy with enterovirus 71 vaccine. Vaccine. 2014;33:1107&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">25444807</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.-L. Type I interferons protect mice against enterovirus71 infection. J.&#xa0;General Virol. 2005;86:3263&#x2013;3269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubauer R.H., Goldstein L., Rabin H., Stebbing N. Stimulation of in&#xa0;vitro immunoglobulin production by interferon-alpha. J.&#xa0;Immunol. 1985;134:299&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">3155465</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharton D. Rift valley fever virus infection in golden syrian hamsters. PloS One. 2015;10:e0116722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301868</ArticleId><ArticleId IdType="pubmed">25607955</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine. 2016. http://www.sinovac.com/?optionid=754&amp;auto_id=803 Sinovac Website Press Releases. (accessed 04.01.16)</Citation></Reference><Reference><Citation>Smee D.F. Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201) PloS One. 2011;6:e26330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192798</ArticleId><ArticleId IdType="pubmed">22022603</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark G.R. How cells respond to interferons. Ann. Rev. Biochem. 1998;67:227&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9759489</ArticleId></ArticleIdList></Reference><Reference><Citation>Takaoka A. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424:516&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">12872134</ArticleId></ArticleIdList></Reference><Reference><Citation>van Boxel-Dezaire A.H., Rani M.R.S., Stark G.R. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006;25:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">16979568</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.M. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J.&#xa0;Infect. Dis. 2003;188:564&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.Q.H. Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha. Virology. 2007;369:206&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761207</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L. Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. Antivir. Ther. 2011;16:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">21311108</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.-C. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013;381:1037&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>